Effects of HMG-CoA reductase inhibitors on growth and differentiation of cultured rat skeletal muscle cells  by Veerkamp, J.H. et al.
q l  
ELSEVIER Biochimica et Biophysica Acta 1315 (1996) 217-222 
BB. Biochi ~mic~a 
et Biophysica A~ta 
Effects of HMG-CoA reductase inhibitors on growth and differentiation 
of cultured rat skeletal muscle cells 
J.H. Veerkamp a,*, J.W.A. Smit b,1, A.A.G.M. Benders a, A. Oosterhof 
a Department of Biochemistry, UniL'ersi~ of Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands 
h Department oflnternal Medicine, Unit,ersi D, of Utrecht, Utrecht, The Netherlands 
Received 16 August 1995; accepted 6 December 1995 
Abstract 
HMG-CoA reductase inhibitors have been associated with skeletal muscle myopathy, ranging from asymptomatic elevations of serum 
creatine kinase (CK) activity to rhabdomyolysis. In this study, we assessed the effects of addition of different concentrations of
simvastatin and pravastatin on growth and differentiation of cultured primary rat skeletal muscle cells. Protein concentration, CK activity 
and percentage CK-MM, which is a parameter for maturation, were determined. Effects were generally stronger if inhibitors were added 
to both growth and differentiation medium rather than only to differentiation medium. Addition of 25 IzM pravastatin caused only a 
decrease of CK activity. Addition of 1-5 /zM simvastatin resulted in a decrease of protein concentration, CK activity and percentage 
CK-MM, whereas 25 /zM simvastatin resulted in cell death. Addition of mevalonic acid or cholesterol could not prevent he effects of 1 
tzM simvastatin. In addition, 1 /zM simvastatin did not influence the cholesterol and phospholipid content of the cells. Superfusion of 
cultured cells with simvastatin concentrations of 10 /zM and higher caused a transient increase of the cytoplasmic calcium concentration 
followed by an apparent second rise and cell puncture. The results indicate that HMG-CoA reductase inhibitors may affect skeletal muscle 
cell regeneration i  vivo by a direct toxic effect on growth and differentiation. 
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1. Introduction 
Inhibitors of 3-hydroxy-3-methylglutaryl-Coenzyme A 
(HMG-CoA) reductase have gained an important place in 
the treatment of hypercholesterolaemia. They inhibit the 
conversion from HMG-CoA into mevalonate, the rate- 
limiting step in cholesterol synthesis, and thereby reduce 
the intracellular pool of cholesterol. This leads to an 
enhanced synthesis of receptors for low density lipoprotein 
(LDL) cholesterol and increased clearance of these parti- 
cles from the circulation [1-4]. The current understanding 
for the mechanism of the hypolipidemic and an- 
tiatherosclerotic action of HMG-CoA reductase inhibitors 
has recently been discussed [5]. 
Abbreviations: CK, creatine kinase; HMG-CoA, 3-hydroxy-3-methyl- 
glutaryl-CoA. 
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Concern has risen about adverse effects on skeletal 
muscle during treatment with these drugs, ranging from 
asymptomatic elevations of serum creatine kinase (CK) 
activity and myopathy to rhabdomyolysis [6-14]. Myopa- 
thy (muscle tenderness and CK levels exceeding more than 
10 times the upper limit of normal) has been found espe- 
cially during combination therapy with gemfibrozil [6-9]. 
Rhabdomyolysis has been observed in combinations with 
erythromycin, niacin or cyclosporin [10-14]. Cyclosporin 
increases systemic levels of HMG-CoA reductase in- 
hibitors due to inhibition of their biliary excretion [1 1]. In 
animals, severe muscle damage can be induced by HMG- 
CoA reductase inhibitors [15-18] especially when com- 
bined with cyclosporin [15]. The lipophilic HMG-CoA 
reductase inhibitor simvastatin seems to have more pro- 
nounced effects than the hydrophilic ompound pravastatin 
[171. 
To evaluate the effects of HMG-CoA reductase in- 
hibitors on skeletal muscle, the influence of hydrophilicity 
of the drug and the potential mechanism for skeletal 
muscle damage, we assessed the effects of simvastatin and 
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pravastatin on growth and differentiation of cultured rat 
skeletal muscle cells, and if present, whether these effects 
are related to inhibition of synthesis of mevalonate and/or 
cholesterol. 
2. Materials and methods 
2.1. Materials 
Ultroser G was purchased from Gibco (Brussels, Bel- 
gium). Simvastatin and pravastatin were obtained from 
Merck, Sharp and Dohme and Bristol Myers Squibb, re- 
spectively. Mevalonic acid and Fura-2/AM were pur- 
chased from Sigma Chemical Co. (St. Louis, MO). Brain 
extract was prepared from brains of 10-day-old Wistar rats. 
Homogenates (100 mg/ml Dulbecco's modified Eagle's 
medium (DMEM)) were centrifuged for 60 min at 100 000 
× g (0-4°C). The supematant was stored at -70°C until 
use .  
2.2. Rat muscle cell cultures 
Satellite cells were isolated from quadriceps muscle of 
10-day-old Wistar albino rats. The muscle (about 100 mg) 
was dissociated according to the dispersion technique of 
Yasin et al. [19]. Mononuclear cells (5 X 104) were plated 
in 35-mm plastic tissue culture dishes in DMEM medium 
containing 20% foetal calf serum, 2% chicken embryo 
extract, and 4 mM glutamine. Cells were cultured at 37°C 
in a humidified CO 2 (5%) atmosphere. After one day, 
non-adhering cells and cell debris were discharged by 
washing twice with the same medium. Subsequently, cells 
were cultured for 5-6 days to confluency in DMEM/4 
mM glutamine containing 4% Ultroser G and 10% rat 
brain extract. Differentiation took place for 6-7 days in 
DMEM/4 mM glutamine medium containing 0.4% U1- 
troser G and 10% rat brain extract. 
Indicated concentrations of pravastatin, simvastatin, 
mevalonic acid or cholesterol were added at day 1 to 
growth medium and/or at confluency to differentiation 
medium. 
2.3. Biochemical assays 
Protein content was assayed according to Lowry et al. 
[20] with bovine serum albumin as standard. CK activity 
was assayed as previously described [21]. For the determi- 
nation of the percentage CK MM (CK-MM) as a measure 
of the maturation grade of muscle cells, this isoenzyme 
was separated from the other CK isoenzymes by anion 
exchange chromatography and analysed as reported [21]. 
Lipids were extracted according to Bligh and Dyer [22]. 
Total cholesterol was determined by an enzymatic method 
(CHOD-PAP, Sigma, St. Louis). Free and esterified 
cholesterol were determined as described before [23]. 
Phospholipids were assayed on the basis of lipid-phos- 
phorus content [24] and phospholipid composition by two- 
dimensional TLC [25]. 
2.4. Ca 2 + homeostasis assays 
The free cytosolic Ca 2+ concentration [Ca2+]i was 
determined in cultured cells using Fura-2 ratio measure- 
ment [26]. Muscle cells were grown on glass coverslips 
(30 × 10 mm) in sera-containing proliferation and differen- 
tiation media [27]. Myotubes were washed with physio- 
logical salt solution (PSS, containing in mM: 125 NaC1, 10 
NaHCO 3, 1 NaH2PO 4, 5 KC1, 2 MgSO4, 1.8 CaC12, 10 
Hepes and 10 glucose, pH 7.4) and loaded with 5 /zM 
Fura-2/AM in PSS for 60 min at 37°C in the presence of 
5% CO 2 and 95% air. Excess of dye was removed by 
Table 1 
Effects of  pravastatin and simvastatin on cultured rat skeletal muscle cells 
Addit ion to: n 
GM DM 
Protein CK  activity CK-MM 
~g/d ish  % U/mg protein % % of total activity 
Control 
- - 8 228 ___ 99 100 0.98 + 0.57 100 73 _ 11 
Pravastatin (/ .tM) 
- 25 5 208 + 89 99 _ 16 0.60 + 0.37 60 + 22 a 76 + 10 
25 - 4 208 _ 113 95 + 15 0.83 + 0.60 76 + 30 75 + 13 
25 25 5 207 + 132 91 + 14 0.43 5:0.12 a 47 + 21 b 69 5 :10  
Simvastatin ( / zM)  
- 0.5 4 196 + 93 91 + 7 0.69 5:0.49 67 + 32 72 + 15 
0.5 0.5 4 191 5:94 91 + 29 0.39 _ 0.13 a 48 + 38 a 62 + 12 
- 1 4 194 + 113 88 5:11 0.62 + 0.32 60 5:20 a 72 + 10 
1 1 7 169 5:107 73 5:19 a 0.36 _ 0.14 a 48 5:27 b 54 5:7  b 
-- 5 4 148 + 111 62 5 :14  a 0.30 -t- 0.24 a 33 + 25 a 60 + 17 
5 5 4 120 5:85 51 _ 13 b 0.32 5:0.21 a 36 5:25 a 51 + 14 a 
Parameters were determined after 6 -7  days in differentiation medium. Creatine kinase MM activity is given as a percentage of  total CK  activity. Values 
are means + S.D. of  the indicated number (n)  of independent experiments. 
GM, growth medium; DM, differentiation medium. Significance: a p < 0.05, b p < 0.01 vs control. 
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washing thrice with PSS. Fluorescence was measured with 
a Shimadzu RF-5000 spectrofluorophotometer a  an emis- 
sion wavelength of 492 nm and alternating excitation 
wavelengths of 340 and 380 nm [26]. During the measure- 
ment the cells were superfused with PSS (4 ml /min ;  
37°C) with additions of simvastatin as indicated in Section 
3. [Ca2+]i was calibrated with 4 /zM ionomycin in the 
presence of l0 mM Ca 2+ (pH 7.7) or 20 mM EGTA (pH 
8.5). 
2.5. Stat ist ical  analyses 
Data are expressed as mean _+ S.D. Statistical analysis 
was performed with an unpaired Student's t-test. A two- 
tailed P < 0.05 was considered significant. 
3. Results 
Optimal conditions for proliferation and differentiation 
of rat muscle cells were applied as previously described 
[27]. Relatively large variations are present in the protein 
content and the CK activity of different experiments due to 
culture variations and different amounts of contaminating 
fibroblasts. Therefore we calculated and compared their 
relative values in the presence of pravastatin, simvastatin 
and other additions. The percentage of CK-MM, a marker 
of muscle cell maturation, showed slight variability be- 
tween the different experiments. 
The effects of addition of different concentrations of
simvastatin and pravastatin on protein content, CK activity 
and percentage CK-MM of cultured rat skeletal muscle 
cells are given in Table 1. In all cases, effects were 
stronger if inhibitors were added to both growth and 
differentiation medium, than only to differentiation 
medium. Pravastatin had only limited effects, even when 
added in high concentrations (25 p~M). The CK activity 
was 60% of control when this concentration was present in 
differentiation medium alone and 47% when present both 
in growth and differentiation medium. The percentages of
CK-MM were unchanged as were the protein yields. In 
contrast, simvastatin had strong effects. In experiments 
Fig. 1. Morphology of cultured rat skeletal muscle cells after 5 days in 
growth medium and 6 days in diffferentiation medium without (a) and 
with (b) 1 /zM simvastatin. The presence of this compound caused the 
occurrence of less and shorter myotubes. 
using 25 /zM simvastatin, cell growth arrested and all cells 
detached from the surface. The presence of 1 /xM simvas- 
tatin caused a marked inhibition of myotube formation 
(Fig. 1). The biochemical analyses reflect the morphologi- 
cal observations. Addition of 0.5 /zM simvastatin to both 
growth and differentiation medium resulted in a signifi- 
cantly decreased CK activity. Concentrations of 1 and 5 
/zM simvastatin resulted in significant decreases of protein 
content and CK activity. The percentage of CK-MM de- 
Table 2 
Effects of mevalonate and cholesterol n rat skeletal muscle cells cultured in the presence ofsimvastatin 
Addition Protein CK activity 
/xg/dish % U/mg protein % 
CK-MM 
% of total activity 
None 147 ___ 25 100 0.41 + 0.22 100 30 +_ 18 
10 /xM mevalonate 126 + 21 92 ± 2 0.27 + 0.03 94 + 2 21 +_ 5 
25 /xM mevalonate 114 _+ 12 83 __+ 7 0.28 _+ 0.06 98 __+ 11 21 ± 8 
50/zM mevalonate 123 _+ 35 84 ± 18 0.45 + 0.32 93 _+ 4 32 +_ 19 
10/xM cholesterol 124 :t: 42 84 ___ 20 0.34 _+ 0.17 82 ± 5 28 _ 13 
Simvastatin (1 /.zM) and indicated concentrations f mevalonate or cholesterol were added to both growth and differentiation medium. Parameters were 
determined after 6-7 days in differentiation medium. Creatine kinase MM activity is given as a percentage of total CK activity. Values are means +S.D. 
of 3 independent xperiments. Values did not change significantly ataddition of mevalonate or cholesterol. 
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Table 3 
Effcts of simvastatin on lipid content and composition of rat skeletal 
muscle cells 
Control Simvastatin 
Total cholesterol 79.3 -+ 3.2 94.3 -+ 14.6 
Free cholesterol 58 _+ 12 48 _+ 7 
Esterified cholesterol 42 _ 12 52 _+ 7 
Total phospholipids 193 + 25 253 + 27 
Phosphatidylinositol 11 + 2 10 + 1 
Phosphatidylserine 13 _ 2 11 + 2 
Sphingomyeline 14 + 1 15 _+ 1 
Phosphatidylcholine 40 ± 2 40 -4- 3 
Phosphatidylethanolamine 22 -+ 2 24 ± 2 
Simvastatin (1 /zM) was added to both growth and differentiation medium. 
Parameters were determined after 6-7 days in differentiation medium. 
Total cholesterol and phospholipids are given in nmol/mg protein, 
separate components in % of total. Values are means -1- S.D. of 3 indepen- 
dent experiments and are not significantly different for simvastatin-ex- 
posed cells. 
creased significantly after addition of 1 and 5 /zM simvas- 
tatin to both growth and differentiation medium. 
As shown in Table 2, the effects of addition of 1 /zM 
simvastatin to growth and differentiation medium could 
not be reversed by concomitant addition of either meval- 
onic acid or cholesterol. In Table 3, the effects of addition 
of 1 /xM simvastatin to growth and differentiation medium 
on lipid content of rat muscle cells are given. No indica- 
tions for a decreased cholesterol content or changes in the 
ratio free/esterified cholesterol were found. The content of 
total phospholipid was not decreased either, nor were 
significant differences observed in the phospholipid com- 
position and the cholesterol/phospholipid ratio. 
The presence of brain extract in the medium was not the 
cause of the absence of counteracting effects of meval- 
onate and cholesterol. Omission of brain extract from 
growth and differentiation medium caused a decrease of 
protein concentration, CK activity and CK-MM percentage 
of control and simvastatin-treated c lls. However, simvas- 
tatin addition had a comparable ffect as on cells cultured 
with brain extract, which could not be restored by addition 
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Fig. 2. Effect of superfusion of cultured rat skeletal muscle cells with 50 
/zM simvastatin i  PSS. Above: the cytoplasmic alcium concentration 
[ Ca2+ ]i measured with the Fura-2 ratio method. Below: the fluorescence 
of Fura-2 at the two excitation wavelengths 340 nm (fixed line) and 380 
nm (dotted line). Two apparent peaks of transient increase of [Ca 2+ ]i are 
visible. The first is a specific increase, the second is caused by leaking 
Fura-2. The simultaneous decrease of the fluorescence at both wave- 
lengths after about 600 s indicates cell damage and leakage of Fura-2 
which disappears at superfusion. 
Table 4 
Effects of simvastatin on the cytoplasmic alcium concentration of cul- 
tured rat skeletal muscle cells 
Concentration simvastatin (/zM) Extracellular calcium 
1.8mM absent 
0 132+18(5) 128i 14(3) 
1 126+ 19 (4) 134± 15 (3) 
10 369+51 (4) a 133_+22 (3) 
50 487-t-63(5) a 131-+17(3) 
Cultured cells (after 6-7 days of differentiation) were superfused with 
PSS containing the indicated simvastatin concentration. In superfusions 
without extracellular calcium, 1 mM EGTA was present. The [Ca 2+ ]i 
was measured by the Fura-2 ratio method. Values of [Ca 2+ ]i (in nM) are 
means+S.D, of the number of cultures given between parentheses. 
Significance: a p < 0.01 vs 0 /zM simvastatin. 
of 50/zM mevalonate or 10 p,M cholesterol to both media 
(data not shown). Higher concentrations of mevalonate or 
cholesterol were not tested. The Ultroser G, indispensable 
for culturing, contributes to the growth and differentiation 
medium 25 /zM and 2.5 /xM cholesterol, respectively. 
The effect of simvastatin on the cytoplasmic alcium 
concentration [Ca2+] i and cell damage was studied in 
cultured cells using Fura-2 ratio measurement. Addition of 
1 /~M simvastatin had no effect on [Ca2+]i, but 10-50 
/zM caused a dose-dependent transient increase (Table 4). 
In contrast o physiological stimulation with acetylcholine 
[26], this increase did not occur in the absence of extracel- 
lular Ca 2÷ and presence of 1 mM EGTA and is thus from 
extracellular origin. If cells were maintained in the pres- 
ence of 10-50 /zM simvastatin the [Ca2+]~ increased a 
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second time and decreased subsequently, but the measure- 
ment of Fura fluorescence showed a decrease at both 
wavelengths (340 and 380 nm), indicating the leakage of 
Fura through the cell membrane (Fig. 2). The time interval 
between the two peaks of Ca R ÷ depended on the simvas- 
tatin concentration. Similar results were obtained with 
cultured human skeletal muscle cells as with those from 
rat. 
4. Discussion 
The present study was performed to get insight into the 
effects of HMG-CoA reductase inhibitors during growth 
and proliferation of skeletal muscle cells. The lipophilic 
compound simvastatin had substantial effects on protein 
yield, CK activity and percentage of CK-MM. In high 
concentration, simvastatin caused cell puncture and in 
culture cell detachment and death. In contrast, pravastatin 
had only a limited effect. Exposure of 8-day-old cultures 
of rat myotubes for 48 h to lovastatin, simvastatin or 
pravastatin also showed the lowest myotoxicity of the last, 
hydrophilic drug [28]. Pravastatin was also much less 
inhibitory in various other types of human extrahepatic 
cells [29-32]. These differences are related to the active 
uptake mechanism of that drug into hepatocytes in contrast 
to into other cell types. The 48-h exposure of 8-day-old 
cultures to simvastatin at a concentration of 4.8 /zM or 
higher caused morphologic injury, including vacuolization, 
changes in cell contour and disappearance of myotubes 
[28]. Protein synthesis and intracellular ATP concentration 
were reduced to 50% of control values at 2 and 4 /xM 
simvastatin, but CK activity at > 24 /zM and cholesterol 
synthesis at 0.1 /zM. Mevalonate (19-100 /zM) reversed 
the inhibition of protein synthesis at 2 /zM simvastatin. 
Although other parameters were assayed, effects of sim- 
vastatin are much larger in our muscle cells, especially if 
the drug was present during both proliferation and differ- 
entiation for 11-13 days. The presence of 0.5-1 /~M 
simvastatin already caused an inhibition by 52% of CK 
activity. The addition of 10-50 /~M mevalonate did not 
reverse the decrease of CK activity and of CK-MM per- 
centage. 
HMG-CoA reductase inhibitors as simvastatin, fluvas- 
tatin and lovastatin inhibit proliferation of arterial wall 
smooth muscle cells, glioma cells and mamma tumor cells 
[29-35]. These effects could be prevented or restored by 
addition of mevalonate, but not by cholesterol. Mevalonate 
is not only a precursor for cholesterol, but also delivers 
isoprenoid groups for synthesis of farnesyl- and geranyl- 
pyrophosphate. These molecules are substrates for post- 
translational modification of proteins (as, e.g., Ras pro- 
teins, nuclear lamins and G-proteins, and for synthesis of 
dolichol and ubiquinone, that have important regulatory 
functions in cell metabolism and growth [36-38]. 
Lovastatin and mevastatin hibited the fusion of L6 rat 
myoblasts and the concurrent increase of CK activity [39]. 
A cause could be the lack of dolichol phosphate oligo- 
saccharide for glycoprotein synthesis [39]. The decreased 
isoprenylation of proteins and the decrease of coenzyme Q
could be other mechanisms of interference with cell growth 
[38,40]. In addition, shortage of cholesterol could affect 
cell membrane stability. However, in the present study, the 
additions of mevalonate and cholesterol were not able to 
prevent he effects of simvastatin on the cultured skeletal 
muscle cells. Moreover, addition of simvastatin to the 
medium did not change the cholesterol and phospholipid 
content of the cells. Apparently, another mechanism, not 
directly coupled to inhibition of mevalonate formation, 
plays a role. Recently it has been suggested that disruption 
of early events in insulin signalling is a potential mecha- 
nism for the antimitogenic activity of lovastatin [41]. The 
concentration of lovastatin necessary to induce growth 
inhibition and apoptosis i  a thousand-fold higher in glioma 
cells than in normal glial cells [42]. So a specific sensitiv- 
ity of cells seems to be involved. Lack of products from 
HMG-CoA may partially be compensated in our cultured 
cells by the addition of brain extract o the medium, but 
also in its absence the same changes were observed. 
Plasma cholesterol-lowering drugs as clofibrate and 
20,25-diazocholesterol have myotoxic effects as well, and 
induce myotonic discharges [43,44], related to a decreased 
chloride conductance of the muscle cell membrane [45]. 
Simvastatin also induced myotonia in rabbits due to a 
decreased chloride conductance [46]. High concentrations 
of simvastatin caused a transient increase in [Ca 2+ ]i of L6 
rat myoblasts followed by cell puncture [47] like we found 
in short-time xperiments and in culture on primary rat 
myotubes. Pravastatin and lower concentrations of simvas- 
tatin had no measurable effect. Cardiomyocytes showed a 
similar acute increase of [Ca 2+ ]i at 20-50/xM simvastatin 
[48]. Lovostatin (1 /zM) in the medium depressed Ca 2+ 
channel activity in cardiac cells in culture and uncoupled 
excitation from contraction [49]. Thus addition of simvas- 
tatin to the culture medium causes dose-dependent effects 
on [Ca 2+ ]i which influence cellular growth and function. 
In conclusion, the present study demonstrates the in- 
hibitory effects of lipophilic HMG-CoA reductase in- 
hibitors on growth and differentiation of cultured muscle 
cells. The absence of a preventive effect of mevalonate and 
the unchanged lipid composition suggest that other mecha- 
nisms than inhibition of HMG-CoA reductase play a role. 
In usual situations of patients, systemic plasma concentra- 
tions of HMG-CoA reductase inhibitors are considerably 
lower than the concentrations used in the present study 
[50,51], and may not lead to muscle damage. Increased 
systemic concentrations, as during combination therapy 
with cyclosporin may especially affect regeneration of 
muscle cells after exercise-induced damage and in this way 
lead to myopathy. 
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